Literature DB >> 17385021

Effect of solid lipid nanoparticles formulation compositions on their size, zeta potential and potential for in vitro pHIS-HIV-hugag transfection.

Rathapon Asasutjarit1, Sven-Iver Lorenzen, Sunee Sirivichayakul, Kiat Ruxrungtham, Uracha Ruktanonchai, Garnpimol C Ritthidej.   

Abstract

PURPOSE: This work was conducted to determine model equations describing the effect of solid lipid nanoparticles (SLN) formulation compositions on their size and zeta potential using the face-centered central composite design and to determine the effect of SLN formulation compositions on the potential for in vitro pHIS-HIV-hugag transfection.
MATERIALS AND METHODS: SLN were prepared by the hot high pressure homogenization technique using cetylpalmitate as lipid matrix at varying concentrations of Tween 80 and Span 85 mixture, dimethyldioctadecyl ammonium bromide (DDAB) and cholesterol. Size and zeta potential used as responses of the design were measured at pH 7.0. The model equations were accepted as statistical significance at p value of less than 0.05. Ability of SLN to form complex with pHIS-HIV-hugag was evaluated by electrophoretic mobility shift assay. In vitro cytotoxicity of SLN was studied in HeLa cells using alamar blue bioassay. The potential of SLN for in vitro pHIS-HIV-hugag transfection was also determined in HeLa cells by western blot technique.
RESULTS: SLN possessed diameter in a range of 136-191 nm and zeta potential 11-61 mV depending on the concentrations of surfactant mixture, DDAB and cholesterol. The regression analysis showed that the model equations of responses fitted well with quadratic equations. The ability of SLN to form complex with pHIS-HIV-hugag was also affected by formulation compositions. In vitro cytotoxicity results demonstrated that HeLa cells were not well tolerant of high concentrations of SLN but still survived in a range of 100-200 microg/ml of SLN in culture medium. The results of transfection study showed ability of SLN to use as a vector for in vitro pHIS-HIV-hugag transfection. However, their potential for in vitro transfection was lower than the established transfection reagent.
CONCLUSIONS: Size and zeta potential of SLN could be predicted from their quadratic model equations achieved by combination of three variables surfactant, DDAB and cholesterol concentrations. In addition, these variables also affected the potential of SLN as a vector for in vitro pHIS-HIV-hugag transfection. The results here provide the framework for further study involving the SLN formulation design for DNA delivery.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17385021     DOI: 10.1007/s11095-007-9234-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  18 in total

Review 1.  Solid lipid nanoparticles: production, characterization and applications.

Authors:  W Mehnert; K Mäder
Journal:  Adv Drug Deliv Rev       Date:  2001-04-25       Impact factor: 15.470

2.  Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulation.

Authors:  Christopher P Locher; David Putnam; Robert Langer; Stephanie A Witt; Brittany M Ashlock; Jay A Levy
Journal:  Immunol Lett       Date:  2003-12-15       Impact factor: 3.685

Review 3.  Nanomedicines for overcoming biological barriers.

Authors:  Maria José Alonso
Journal:  Biomed Pharmacother       Date:  2004-04       Impact factor: 6.529

4.  The potential role of proteoglycans in cationic lipid-mediated gene delivery. Studies of the interaction of cationic lipid-DNA complexes with model glycosaminoglycans.

Authors:  C M Wiethoff; J G Smith; G S Koe; C R Middaugh
Journal:  J Biol Chem       Date:  2001-07-06       Impact factor: 5.157

Review 5.  Basics of the virology of HIV-1 and its replication.

Authors:  Saleta Sierra; Bernd Kupfer; Rolf Kaiser
Journal:  J Clin Virol       Date:  2005-09-29       Impact factor: 3.168

6.  Assessing the potential of fish cell lines as tools for the cytotoxicity testing of estuarine sediment aqueous elutriates.

Authors:  M Davoren; S Ní Shúilleabháin; M G J Hartl; D Sheehan; N M O'Brien; J O'Halloran; F N A M Van Pelt; C Mothersill
Journal:  Toxicol In Vitro       Date:  2005-04       Impact factor: 3.500

7.  Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA.

Authors:  C Olbrich; U Bakowsky; C M Lehr; R H Müller; C Kneuer
Journal:  J Control Release       Date:  2001-12-13       Impact factor: 9.776

8.  Topical immunization using nanoengineered genetic vaccines.

Authors:  Zhengrong Cui; Russell J Mumper
Journal:  J Control Release       Date:  2002-05-17       Impact factor: 9.776

9.  Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study.

Authors:  J Vandervoort; A Ludwig
Journal:  Int J Pharm       Date:  2002-05-15       Impact factor: 5.875

10.  Solid lipid nanoparticles bearing flurbiprofen for transdermal delivery.

Authors:  S K Jain; M K Chourasia; R Masuriha; V Soni; A Jain; Nitin K Jain; Y Gupta
Journal:  Drug Deliv       Date:  2005 Jul-Aug       Impact factor: 6.419

View more
  13 in total

1.  pH-responsive nanoparticles releasing tenofovir intended for the prevention of HIV transmission.

Authors:  Tao Zhang; Timothy F Sturgis; Bi-Botti C Youan
Journal:  Eur J Pharm Biopharm       Date:  2011-06-26       Impact factor: 5.571

2.  Mixed backbone antisense glucosylceramide synthase oligonucleotide (MBO-asGCS) loaded solid lipid nanoparticles: in vitro characterization and reversal of multidrug resistance in NCI/ADR-RES cells.

Authors:  Akhtar Siddiqui; Gauri Anand Patwardhan; Yong-Yu Liu; Sami Nazzal
Journal:  Int J Pharm       Date:  2010-09-15       Impact factor: 5.875

3.  D-optimal mixture design for optimization of topical dapsone niosomes: in vitro characterization and in vivo activity against Cutibacterium acnes.

Authors:  Basant A Habib; Nourtan F Abdeltawab; Ibtehal Salah Ad-Din
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

4.  Characterization and evaluation of 5-fluorouracil-loaded solid lipid nanoparticles prepared via a temperature-modulated solidification technique.

Authors:  Meghavi N Patel; Sushant Lakkadwala; Mohamed S Majrad; Elisha R Injeti; Steven M Gollmer; Zahoor A Shah; Sai Hanuman Sagar Boddu; Jerry Nesamony
Journal:  AAPS PharmSciTech       Date:  2014-07-18       Impact factor: 3.246

Review 5.  A review of the tortuous path of nonviral gene delivery and recent progress.

Authors:  Divya Sharma; Sanjay Arora; Jagdish Singh; Buddhadev Layek
Journal:  Int J Biol Macromol       Date:  2021-06-01       Impact factor: 8.025

6.  Efficient Gene Silencing by Self-Assembled Complexes of siRNA and Symmetrical Fatty Acid Amides of Spermine.

Authors:  Abdelkader A Metwally; Charareh Pourzand; Ian S Blagbrough
Journal:  Pharmaceutics       Date:  2011-03-25       Impact factor: 6.321

7.  Self-Assembled Lipoplexes of Short Interfering RNA (siRNA) Using Spermine-Based Fatty Acid Amide Guanidines: Effect on Gene Silencing Efficiency.

Authors:  Abdelkader A Metwally; Ian S Blagbrough
Journal:  Pharmaceutics       Date:  2011-07-13       Impact factor: 6.321

8.  Formulation, optimization and characterization of allantoin-loaded chitosan nanoparticles to alleviate ethanol-induced gastric ulcer: in-vitro and in-vivo studies.

Authors:  Reham Mokhtar Aman; Randa A Zaghloul; Marwa S El-Dahhan
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

9.  Therapeutic Use of 3β-[N-(N',N'-Dimethylaminoethane) Carbamoyl] Cholesterol-Modified PLGA Nanospheres as Gene Delivery Vehicles for Spinal Cord Injury.

Authors:  So-Jung Gwak; Yeomin Yun; Do Heum Yoon; Keung Nyun Kim; Yoon Ha
Journal:  PLoS One       Date:  2016-01-29       Impact factor: 3.240

10.  Lipid Nanoparticles Containing Mixtures of Antioxidants to Improve Skin Care and Cancer Prevention.

Authors:  Catarina Gonçalves; Maria João Ramalho; Renata Silva; Vera Silva; Rita Marques-Oliveira; Ana Catarina Silva; Maria Carmo Pereira; Joana A Loureiro
Journal:  Pharmaceutics       Date:  2021-11-30       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.